AbbVie Genmab Lymphoma Drug Cuts Progression Risk
AbbVie and Genmab reported their lymphoma drug combination reduced disease progression or death risk by 51% in a late-stage study. The trial evaluated epcoritamab with R-CHOP for newly diagnosed patients.
Xurve View
Insights:
Xurve View
ABBVIE INC and GENMAB A/S -SP ADR said their drug combination cut lymphoma progression risk by 51% in a late-stage trial. The study evaluated epcoritamab paired with R-CHOP in newly diagnosed patients with diffuse large B-cell lymphoma. The trial marks the first late-stage study of a bispecific antibody to improve first-line progression-free survival.
